Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ixekizumab Formulations in Healthy Subjects
NCT03848416Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Ixekizumab at Day 85 and Area Under the Plasma Concentration Versus Time Curve at Day 85. Started Jan 2019; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03848416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848416.